Meeting
2015 ASCO Annual Meeting
Real-world treatment patterns, healthcare resource utilization (HRU), and costs of initial line of therapy (LOT1) in multiple myeloma (MM).
Authors
Stacey DaCosta Byfield
OptumInsight, Eden Prairie, MN
Stacey DaCosta Byfield , Tim Bancroft , Esprit Ma , Vijayveer Bonthapally , April H. Teitelbaum
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6603)
DOI
10.1200/jco.2015.33.15_suppl.6603
Abstract #
6603
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry.
First Author: Howard R. Terebelo
Poster
2023 ASCO Annual Meeting
Identification of genes encoding targets associated with adverse events in multiple myeloma.
First Author: Xuan Xu
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
First Author: Stefan Knop